Grace Wong-Sarad Sells 5,165 Shares of Alector (NASDAQ:ALEC) Stock

Alector, Inc. (NASDAQ:ALEC) insider Grace Wong-Sarad sold 5,165 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $2.67, for a total transaction of $13,790.55. Following the sale, the insider owned 109,640 shares in the company, valued at approximately $292,738.80. The trade was a 4.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Grace Wong-Sarad also recently made the following trade(s):

• On Friday, September 4th, Grace Wong-Sarad sold 3,625 shares of Alector stock. The stock was sold at an average price of $2.51, for a total transaction of $9,098.75.
• On Wednesday, September 2nd, Grace Wong-Sarad sold 656 shares of Alector stock. The stock was sold at an average price of $2.75, for a total transaction of $1,804.00.

Alector Trading Down 2.0%

ALEC opened at $2.46 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.26 and a current ratio of 5.26. The stock’s 50 day moving average price is $1.91 and its 200-day moving average price is $2.06. Alector, Inc. has a one year low of $1.09 and a one year high of $3.40. The stock has a market cap of $274.68 million, a price-to-earnings ratio of -2.24 and a beta of 0.65.

Alector (NASDAQ:ALEC) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%.The company had revenue of $3.32 million for the quarter, compared to the consensus estimate of $1.71 million. On average, equities analysts forecast that Alector, Inc. will post -0.87 EPS for the current year.

Institutional Investors Weigh In On Alector

Hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Alector during the second quarter valued at approximately $15,774,000. Nantahala Capital Management LLC purchased a new stake in Alector during the second quarter worth $8,679,399. Foresite Capital Management IV LLC purchased a new stake in Alector during the fourth quarter worth $6,064,000. Merck & Co. Inc. bought a new stake in Alector during the 2nd quarter valued at $7,126,896. Finally, Balyasny Asset Management L.P. bought a new stake in Alector during the 4th quarter valued at $5,094,000. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Analyst Ratings Changes

ALEC has been the topic of several recent analyst reports. Weiss Ratings raised shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Wall Street Zen upgraded shares of Alector from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $3.62.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.